Torsten Kessler

Dr. Torsten Kessler

Department of Medicine A, Hematology, Oncology, University Hospital Muenster, D-48149 Muenster, Germany
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Leukemia
Verified
Journal Article
Closed access
Teresa PadroTeresa Padro
Teresa Padro
RBR Bieker
R Bieker
SRS Ruiz
S Ruiz
MSM Steins
M Steins
SRS Retzlaff
S Retzlaff
RMRm Mesters
Rm Mesters

26 December 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SSSteve Silletti
Steve Silletti
Torsten KesslerTorsten Kessler
Torsten Kessler
JGJoel Goldberg
Joel Goldberg
DBDale L. Boger
Dale L. Boger
DCDavid A. Cheresh
David A. Cheresh
Matrix metalloproteinase 2 (MMP2) can associate with integrin αvβ3 on the surface of endothelial cells, thereby promoting vascular invasion. Here, we describe an organic molecule (TSRI265) selected for its ability to bind to integrin αvβ3 and block αvβ3 interaction with MMP2. Although disrupting αvβ3/MMP2 complex formation, TSRI265 has no effect on αvβ3 binding to its extracellular matrix ligand vitronectin and does not influence MMP2 activation or catalytic activity directly. However, TSRI265 acts as a potent antiangiogenic agent and thereby blocks tumor growth in vivo. These findings suggest that activated MMP2 does not facilitate vascular invasion during angiogenesis unless it forms a complex with αvβ3 on the endothelial cell surface. By disrupting endothelial cell invasion without broadly suppressing cell adhesion or MMP function, the use of compounds such as TSRI265 may provide a novel therapeutic approach for diseases associated with uncontrolled angiogenesis.

14 May 2009 in Blood
Verified
Journal Article
Closed access
RBRalf Bieker
Ralf Bieker
Torsten KesslerTorsten Kessler
Torsten Kessler
CSChristian Schwöppe
Christian Schwöppe
Teresa PadroTeresa Padro
Teresa Padro
TPThorsten Persigehl
Thorsten Persigehl
WBWolfgang E. Berdel
Wolfgang E. Berdel
We induced thrombosis of blood vessels in solid tumors in mice by a fusion protein consisting of the extracellular domain of tissue factor (truncated tissue factor, tTF) and the peptide GNGRAHA, targeting aminopeptidase N (CD13) and the integrin αvβ3 (CD51/CD61) on tumor vascular endothelium. The designed fusion protein tTF-NGR retained its thrombogenic activity as demonstrated by coagulation assays. In vivo studies in mice bearing established human adenocarcinoma (A549), melanoma (M21), and fibrosarcoma (HT1080) revealed that systemic administration of tTF-NGR induced partial or complete thrombotic occlusion of tumor vessels as shown by histologic analysis. tTF-NGR, but not untargeted tTF, induced significant tumor growth retardation or regression in all 3 types of solid tumors. Thrombosis induction in tumor vessels by tTF-NGR was also shown by contrast enhanced magnetic resonance imaging (MRI). In the human fibrosarcoma xenograft model, MRI revealed a significant reduction of tumor perfusion by administration of tTF-NGR. Clinical first-in-man application of low dosages of this targeted coagulation factor revealed good tolerability and decreased tumor perfusion as measured by MRI. Targeted thrombosis in the tumor vasculature induced by tTF-NGR may be a promising strategy for the treatment of cancer.

17 October 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
APAlexander Pfeifer
Alexander Pfeifer
Torsten KesslerTorsten Kessler
Torsten Kessler
SSSteve Silletti
Steve Silletti
DCDavid A. Cheresh
David A. Cheresh
IVInder M. Verma
Inder M. Verma
Modulation of the balance between pro- and antiangiogenic factors holds great promise for the treatment of a broad spectrum of human disease ranging from ischemic heart disease to cancer. This requires both the identification of angiogenic regulators and their efficient delivery to target organs. Here, we demonstrate the use of a noncatalytic fragment of matrix metalloproteinase 2 (termed PEX) delivered by lentiviral vectors in different angiogenesis models. Transduction of human endothelial cells with PEX virus suppressed endothelial invasion and formation of capillary-like structures without affecting chemotaxis in vitro . Lentiviral delivery of PEX blocked basic fibroblast growth factor-induced matrix metalloproteinase 2 activation and angiogenesis on chicken chorioallantoic membranes. PEX expression also inhibited tumor-induced angiogenesis and tumor growth in a nude mouse model. Thus, our study shows that lentiviral vectors can deliver sufficient quantities of antiangiogenic substances to achieve therapeutic effects in vivo .

1 March 2001 in Molecular Therapy
Verified
Journal Article
Open access
APAlexander Pfeifer
Alexander Pfeifer
Torsten KesslerTorsten Kessler
Torsten Kessler
MYMeng Yang
Meng Yang
EBEugene Baranov
Eugene Baranov
NKNeeltje Kootstra
Neeltje Kootstra
IVInder M. Verma
Inder M. Verma
Mt is a cross-disciplinary biomedical journal devoted to publishing the most exciting advances in pharmacology and therapeutics, as they pertain to advances in translational and clinical medicine. It is recognized as one of the most prestigious journals in the field. With an impact factor of 6.825*, mt ranks in the top 4.2% of scientific journals in the latest Science Citation Index. Published monthly online and in print.

28 August 2014 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MMMichael Mohr
Michael Mohr
CSChristoph Schliemann
Christoph Schliemann
CBChristoph Biermann
Christoph Biermann
LSLars-Henning Schmidt
Lars-Henning Schmidt
Torsten KesslerTorsten Kessler
Torsten Kessler
WBWolfgang E. Berdel
Wolfgang E. Berdel
Recurrent respiratory papillomatosis (RRP) is a primary benign disease, which is characterized by papillomatous growth in the respiratory tract. Malignant transformation occurs in only 3‑5% of cases, however, local growth of the benign papillomas is interpreted as clinically malignant in a markedly higher proportion of patients. Local surgical or endoscopic interventional debulking or excision is currently the commonly selected treatment method and antiviral therapy is a potential adjuvant approach. However, the long‑term management of RRP patients, who commonly require multiple procedures over numerous years, is challenging and the overall therapeutic armamentarium remains unsatisfactory. The administration of systemic bevacizumab treatment in a series of five patients with long histories of RRP, who required repeated local interventions to control papilloma growth is evaluated. Treatment with the anti‑vascular endothelial growth factor (VEGF) antibody bevacizumab was administered at a dose of 5 mg/kg (n=1), 10 mg/kg (n=3) or 15 mg/kg (n=1) intravenously to the five RRP patients, who were clinically classified as exhibiting progressive disease. Endoscopic evaluations were performed prior to the first infusion of bevacizumab and intermittently at variable time points during the course of therapy. Histopathological analyses were performed using pre‑ and post‑treatment papilloma biopsies, including immunohistochemical analyses of VEGF and phosphorylated VEGF receptor (VEGFR)‑2 expression. The patients received between three and 16 courses of bevacizumab (median, six courses). The first course was initiated when progression following the previous intervention was observed. An immediate response to bevacizumab treatment was demonstrated in all five RRP patients. While the cumulative number of interventions in the five patients was 18 throughout the 12 months prior to the initiation of bevacizumab treatment, only one patient required interventional treatment due to a malignant transformation during the 12 months following treatment with bevacizumab (18 vs. 1 interventions, P=0.042). Histopathological analyses revealed regressive perivascular edema and normalization of the vascular structure, however, immunohistochemical analyses of the VEGF and phosphorylated VEGFR‑2 expression did not demonstrate any changes following therapy. Due to the limited number of alternative treatments, VEGF‑targeted therapies may represent a promising novel strategy in the treatment of RRP, which may have the potential to modify the current treatment standards, particularly in patients with poorly accessible papilloma lesions, however, this requires further investigation in clinical trials.